UCB strengthens cardiovascular and metabolic product portfolio in Germany

UCB and Novartis have signed a licensing agreement for cardiovascular and diabetes products in Germany.

UCB and Novartis have signed a licensing agreement for cardiovascular and diabetes products in Germany.

Under the agreement, UCB has extended commercial rights to the cardiovascular drug Provas (valsartan) for the German market beyond 2011 and has licensed in commercial rights for anti-hypertension drugs Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT).

UCB will also co-market two new oral anti-diabetics, Jalra and Icandra (vildagliptin and vildagliptin and metformin).

"With this agreement we are building on our strengths in Germany," said Willy Cnops, vice president of UCB and managing director of its German business.

"We are extending our cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date in line with UCB's ambitions to offer the best medicines to our patients."

UCB Germany is an affiliate of Belgian biopharmaceutical firm UCB, which focuses on medicines for central nervous system and immunology disorders.

Companies